LPL and metabolic syndrome: Both behaviors contribute for example to dyslipidemia by inhibiting lipoprotein lipase activity, leading to higher triglyceride levels and lower HDL-cholesterol [39, 46], thus increasing the risk of cardiovascular events and mortality.